UBS Group’s ANI Pharmaceuticals ANIP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2013
Q3
– Sell
-500
Closed -$3K – 10322
2013
Q2
$3K Hold
500
– – ﹤0.01% 9573

Other funds holding ANIP

UBS Group's ANIP Position: Q3 2026 in Review

UBS Group increased its ANI Pharmaceuticals (ANIP) stake by 109% in Q3 2026, buying an estimated $24.9M and bringing the position to 621,335 shares worth $45.1M. The position accounts for 0.01% of the portfolio, ranked #1801.

UBS Group first reported a position in ANIP in Q2 2013 and has held it in 53 quarters since. The position peaked at $54M in Q3 2025. 291 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • UBS Group held 621,335 shares of ANI Pharmaceuticals worth $45.1M as of Q3 2026.
  • UBS Group bought 323,796 ANI Pharmaceuticals shares in Q3 2026, an estimated $24.9M.
  • ANI Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q3 2026, its #1801 holding.
  • UBS Group first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • UBS Group's ANI Pharmaceuticals position peaked at $54M in Q3 2025.
  • 291 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.